SEC Form 4 · accession 0001628656-17-000004
MYRIAD GENETICS INC · MYGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bernard Tobin
Officer — President Crescendo BioScience
Period of report
Sep 13, 2017
Accepted (ET)
Sep 15, 2017 · 4:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899923
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 13, 2017 | A | 40,000 | $0.00 | A | 157,862 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on September 25, 2018, 25% on September 25, 2019, 25% on September 25, 2020, and 25% on September 25, 2021.